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Abstract
Background: A population of breast cancer patients exists who, for various reasons, never received adjuvant post-
operative tamoxifen (TAM). This study was aimed to evaluate the role of late TAM in these patients.
Methods: From 1997 to 2003, patients aged 35 to 75 years, operated more than 2 years previously for monolateral 
breast cancer without adjuvant TAM, with no signs of metastases and no contraindication to TAM were randomized to 
TAM 20 mg/day orally for 2 years or follow-up alone. Events were categorized as locoregional relapse, distant 
metastases, metachronous breast cancer, tumours other than breast cancer and death from any causes, whichever 
occurred first. The sample size (197 patients per arm, plus 10% allowance) was based on the assumption of a 30% 
decrease in the number of events occurring at a rate of 5% annually in the 10 years following randomization. Four 
hundred and thirty-three patients were randomized in the study (TAM 217, follow-up 216). Patients characteristics 
(TAM/follow-up) included: median age 55/55 years, median time from surgery 25/25 months (range, 25-288/25-294), in 
situ carcinoma 18/24, oestrogen receptor (ER) positive in 75/68, negative in 70/57, unknown in 72/91 patients. Previous 
adjuvant treatment included chemotherapy in 131/120 and an LHRH analogue in 11/13 patients.
Results: Thirty-six patients prematurely discontinued TAM after a median of 1 month, mostly because of subjective 
intolerance. Eighty-three events (TAM 39, follow-up 44) occurred: locoregional relapse in 10/8, distant metastases in 14/
16, metachronous breast cancer in 4/10, other tumours in 11/10 patients. Less ER-positive secondary breast cancers 
occurred in the TAM treated patients than in follow-up patients (1 vs 10, p = 0.005). Event-free survival was similar in 
both groups of patients.
Conclusions: This 5-year analysis revealed significantly less metachronous ER-positive breast cancers in the TAM 
treated patients. No other statistically significant differences have emerged thus far.
Background
Breast cancer patients present a lifelong increased risk of
a contralateral new breast cancer, with a reported inci-
dence of 0.5-1% annually, translating into a 10-20% risk in
long-term survivors [1-4]. In addition, local relapses and
distant metastases occur even long time after local cura-
tive treatment [5].
Tamoxifen (TAM) has a well defined role in the postop-
erative management of oestrogen receptor (ER) positive
breast cancer with a significant impact upon locoregional
relapse, the development of distant metastases and of
contralateral metachronous breast cancer [5]. In addition,
r a n d o m i s e d  s t u d i e s  h a v e  s h o w n  t h a t  T A M  i s  a b l e  t o
reduce the incidence of primary breast cancer in various
settings: (high-risk patients [6-8] and hysterectomised
low-risk patients [9]).
In spite of the widespread use of TAM, a large popula-
tion of breast cancer patients who never received TAM
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exists, mostly going back to past decades, either because
of the low risk of relapse or because only chemotherapy
was planned.
Whether this population of breast cancer patients still
has a chance to derive the well known benefits of TAM is
not known.
The present randomised study was aimed to evaluate
the role of late TAM in patients previously operated for
breast cancer who did not receive postoperative TAM.
The 5-year results of this study are the subject of the
present report.
Methods
From July 1997 to May 2003 all eligible patients seen at
our Institution were considered for the study. Eligibility
criteria included histologically proven infiltrating or in
situ breast cancer, age between 35 and 75 years, radical
surgery for monolateral breast cancer more than 2 years
previously, no signs of breast cancer, no contraindication
to TAM and informed consent.
Disease stage at the time of surgery was retrospectively
classified according to the TNM classification. ER status
was defined as positive when ≥10% of the tumour cells
expressed ER by immunohistochemical assay or when
>10 fmol/mg of cytosol protein by ligand-binding assay
were present.
A recent negative mammogram, chest X-rays, bone
scan and liver ultrasound were requested before random-
ization.
Patients were stratified according to the time elapsed
from local treatment (2-5 years versus more than 5 years)
and randomised to TAM 20 mg/day orally for 2 years or
follow-up alone.
The follow-up procedures were identical in the two
arms and included patient history, a physical examination
and serum biochemistry with Ca 15.3 every 6 months for
the first 2 years and yearly thereafter, an annual gynaeco-
logic evaluation and an annual mammogram. All other
examinations were planned only if symptoms occurred.
Statistical considerations
The primary endpoint was event-free survival. Events
were categorised as locoregional relapse, distant metasta-
ses, metachronous breast cancer, secondary tumours
other than breast cancer and death from any other
causes, whichever occurred first. Event-free survival was
defined as the time between randomisation and the man-
ifestation of an event.
Secondary endpoints included overall survival and the
toxicity profile. The toxic effects of TAM were catego-
rized according to the WHO criteria [10]. Overall sur-
vival was defined as the time interval between
randomisation and death for any cause.
Comparison of proportions was done by means of Chi-
square analysis of Fisher's exact test when appropriate.
The Kaplan Meier method [11] was used to plot event-
free survival and overall survival. The statistical analyses
were carried out using the SAS Software version 9.13
(SAS Institute Inc., Cary, North Carolina, USA).
The sample size (197 patients per arm, plus 10% allow-
ance) was based on the assumption of a 30% decrease in
the number of events occurring at a rate of 5% yearly in
the 10 years following randomization.
The study was approved by the institutional Ethical
Committee (registration number: CRO-14-1997).
Results
From March 1997 to May 2003, 433 patients were ran-
domized in the study (TAM 217, follow-up 216). The
main characteristics of the patients are reported in Table
1.
Figure 1 represents a CONSORT diagram for the study.
Of the 217 patients randomized to the TAM group, 15
never started the therapy.
In general, TAM was well tolerated and no G4 events
were recorded. There were no statistically significant dif-
ferences in the side effects between the two arms, apart
from hot flashes which occurred more frequently in the
TAM patients (51%) than in those in follow-up (5%).
Thirty-six patients discontinued TAM after a median of
one month due to toxic effects or subjective intolerance.
The reasons for discontinuation are reported in Table 2.
At the time of analysis, the median follow-up period for
the TAM group was 89 months, while for the follow-up
group this was 88 months.
The number and type of events are summarized in
Table 3.
Thirty-nine events occurred in the TAM group while
44 events occurred in the control group. The difference
was not statistically significant.
Less ER-positive secondary breast cancers occurred in
the TAM treated patients (p = 0.005). None of the other
differences observed was statistically significant.
In the TAM group, 1 contralateral breast cancer
occurred in the 75 patients whose original tumour was
ER-positive, 1 in the 68 patients with ER-negative tumour
and 2 in the 73 patients whose ER status was unknown. In
the follow-up group, the corresponding figures were 1/
68, 3/58 and 6/91. None of these differences were statisti-
cally significant.
Event-free survival curves (all randomised patients) are
reported in Figure 2. No statistically significant difference
between the curves can be noted. The five-year event-
free survival was 91% for the TAM patients and 88% for
the follow-up group.Veronesi et al. BMC Cancer 2010, 10:205
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Event-free survival curves of patients with known ER
positivity are shown in Figure 3. Although there appears
to be a trend towards a better event-free survival in the
TAM treated group, the curves do not differ in a statisti-
cally significant manner. A planned subgroup analysis
was performed according to the time from surgery (2-5
years vs more than 5 years) and adjuvant medical treat-
ment (yes vs no). No statistically significant differences
emerged (curves not shown).
Nineteen TAM patients and 18 follow-up patients died
after a median of 67 and 53 months respectively. Survival
curves (not shown) were superimposable.
Table 1: Patient Characteristics
TAM (n = 217) FU (n = 216) p value
Median age (range) 55 yrs (28-75) 55 yrs (26-75)
Time from surgery
2-5 years 121 120 p = 0.97
>5 years 96 96
Median time from surgery in 
months (range)
25 (25-288) 25 (25-294) p = 0.99
Menopausal status
Premenopausal 33 33 p = 0.98
Postmenopausal 184 183
Stage at diagnosis
Tis 18 24
I8 4 8 2
II 87 88 p = 0.52
III 28 18
Unknown 2 3
Nodal status
Positive 74 76
Negative 126 119 p = 0.72
Unknown 17 21
Previous hysterectomy 39 36 p = 0.72
Er status
ER+ 75 68
ER- 68 58 p = 0.21
ER unknown 73 91
Previous medical treatment
Anthracyclines 44 40
CMF 87 80
LH-RH analogue for 2 
years
11 13 p = 0.79
No treatment 75 83Veronesi et al. BMC Cancer 2010, 10:205
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Discussion
TAM has proven to benefit all groups of patients with
breast cancer and hormone sensitive tumours in the adju-
vant setting and has a role in the prevention of breast
cancer in several situations. The present study was aimed
to investigate the role of TAM in patients operated for
breast cancer who had never received TAM and it was
powered to detect an effect in the order of that ascer-
tained in the adjuvant setting.
The eligible population consisted partly of premeno-
pausal patients who, several years before, did not receive
TAM either because of a low risk of relapse or because
they had received oophorectomy, chemotherapy or both.
It should be noted that the acceptance of TAM as a stan-
dard therapy for premenopausal patients with hormone
sensitive tumour was slower in Italy than in other coun-
tries and that, as a consequence, a certain population of
patients diagnosed and treated in the Eighties and early
Nineties who never received TAM according to the pres-
ent indications exists. In addition, both pre- and post-
menopausal patients who did not receive TAM either
because their tumour was hormone insensitive or for
other reasons, were eligible for the study. One hundred
and sixty-four patients had an unknown ER status. Efforts
were made to retrieve the information whenever possible,
but some data of patients who had been operated else-
where a long time before are missing. This may reflect the
situation in contexts where it is less likely that the
patients received tamoxifen as appropriate after primary
treatment. Obviously, the lack of ER evaluation in a rele-
vant proportion of the study population represents a
major limitation of the study.
Figure 1 Consort Diagram.
Patients randomly 
assigned 
N = 433
TAM
N = 217
Follow-up 
N = 216
Never started 
TAM
N = 15
Started  
N = 202
Follow-up 
N = 216
Intention to treat  
Event-free survival  
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At this 5-year analysis, few events (n = 83) occurred
and only a minority of these (n = 30) were of metastatic
nature. This was predictable, taking into account the
nature of the study in which the selection mechanism
tended to exclude from randomization biologically
aggressive tumours with a high propensity to early
relapse. In addition, the majority of patients had received
active adjuvant treatment, which may have contributed to
the low number of events making difficult to ascertain
the role of tamoxifen.
Some differences in outcome were detected in the two
groups.
A statistically significant smaller number (1 vs 10) of
ER-positive contralateral breast cancers, a trend towards
fewer contralateral breast cancers (4 vs 10) and to a lon-
ger event-free survival in ER-positive cases were noted in
the TAM-treated group. Contralateral ER-negative breast
cancer occurred more frequently in the TAM group, sup-
porting the inability of TAM to prevent ER-negative sec-
ondary tumours as previously described [12].
TAM was basically well tolerated and no serious
adverse events occurred. The toxicity encountered was
mostly related to the hormonal effects of TAM. Only one
case of endometrial cancer occurred in a TAM-treated
patient.
In the only published study with a design and size com-
parable to that of the present study, Delozier et al [13]
noted 109 events in a population of 494 randomized
patients followed-up for 10 years. An 83% 10-year dis-
ease-free survival in TAM- treated patients was reported,
as compared to 75% in controls (p = 0.01). No difference
in overall survival in the whole population was noted, but
subgroups with node-positive or ER-positive disease had
a better survival with TAM. Different from our study,
TAM was planned to be administered continuously life-
long at the dose of 30 mg/day.
Table 2: Reasons for Tam Discontinuation
Subjective intolerance 7
Phlebitis/vascular effects 5
Skin rash 4
Allergy 2
Anxiety 2
Cardiopalm/arrhythmia 2
Insomnia 2
Vertigo 2
Headache 2
Vaginitis 4
Other 4
Table 3: Events
TAM (n = 217) FU (n = 216) p value
N. of events 39 44 p = 0.53
Local relapse 10 8 p = 0.64
Contralateral BC 4 10 p = 0.11
ER+ 1 10 p = 0.005
ER- 3 0 p = 0.24
Distant metastases
- Lung
- Liver
- Brain
- Bone
- Lymph nodes
- Peritoneal carcinosis
14
7
0
3
2
1
1
16
2
3
1
6
4
0
p = 0.70
p = 0.18
p = 0.12
p = 0.62
p = 0.18
p = 0.22
p = 1.00
Second primary neoplasm 11 10 p = 1.00
Endometrial cancer 1 0 p = 1.00Veronesi et al. BMC Cancer 2010, 10:205
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In a smaller study [14], 2 years of TAM had no influ-
ence upon disease-free survival, although there were
more deaths (mostly unrelated to breast cancer) in the
placebo group.
Delozier's data bring into question the adequacy of a 2-
year treatment with TAM as compared to a standard 5-
year treatment or longer. When designing our study, we
were particularly worried by the carcinogenic effects of
TAM, especially in this population of patients with a high
likelihood of permanent cure, and decided to limit the
treatment duration to 2 years, which had shown an effect
in previous randomized studies as demonstrated both in
the 1992 and the 1998 Overviews [15,16], with a respec-
tive 27% and 24% reduction of recurrences. Subsequent
2005 Overview data [5] continued to indicate a 21%
reduction in the risk of recurrence (26% in ER-positive,
11% in ER-poor cases) following 1-2 years of adjuvant
TAM. In a recent study [17], 2 years of TAM was able to
halve the risk of contralateral breast cancer in premeno-
pausal women of all ages, although the effect was more
evident in women younger than 40 years. Interestingly,
the protective effect of 2 years of TAM was persistent
during the whole follow-up period (median follow-up, 14
years).
Regarding the use of TAM in ER-negative tumours,
although the 1998 Overview [16] showed a beneficial
e f f e c t  o f  T A M ,  s u b s e q u e n t  r e p o r t s  [ 5 , 1 8 ]  i n d i c a t e d  a
potential deleterious effect of 5 years of TAM. This has
not emerged in this study, where TAM was used in a dif-
ferent setting.
At the time this study was designed, the effect of TAM
on contralateral breast cancer appeared to be indepen-
dent of ER status [15,16]. Subsequent studies indicated
that its effect is limited to, or prevalent in women who
originally had ER-positive breast cancer [5]. In our study,
the results thus far are inconclusive on this issue.
Conclusions
This 5-year analysis has not shown, apart from a smaller
number of ER-positive contralateral breast cancers, a sta-
tistically significant effect of TAM as used. However, the
number of events was low and a longer follow-up with
additional events is needed to confirm the trends noted,
particularly in terms of reduction in ER-positive contral-
ateral breast cancer, and to possibly add another piece of
evidence to the spectrum of activity of this eclectic drug.
Finally, we would like to point out that, although in
Western societies the vast majority of patients with ER-
Figure 2 Event-Free Survival (All randomized patients).
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positive breast cancer receive postoperative TAM, this is
n o t  t r u e  i n  l a r g e  p a r t s  o f  t h e  w o r l d .  S t r a t e g i e s  o f  l a t e
intervention, therefore, may have a place in the future in
that context.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AV designed the study. AV, GM, MDM, DC, SS and DL managed the patients. EB
performed the statistical analysis. All authors participated in the manuscript
preparation. All authors read and approved the final manuscript.
Acknowledgements
The authors gratefully thank Anna Maria Colussi for her assistance in editing 
the text and Monica Oliva for technical assistance.
Author Details
1Division of Medical Oncology C, National Cancer Institute, Via Franco Gallini 2, 
33081 Aviano, Italy and 2Epidemiology Unit, National Cancer Institute, Via 
Franco Gallini 2, 33081 Aviano, Italy
References
1. Robbins GF, Berg JW: Bilateral primary breast cancer. A prospective 
clinicopathological study.  Cancer 1964, 17:1501-1527.
2. Healey EA, Cook F, Orav EJ, Schnitt SJ, Connally JL, Harris JR: Contralateral 
breast cancer: clinical characteristics and impact on prognosis.  J Clin 
Oncol 1993, 11:1545-1552.
3. Broet P, de la Rochefordière A, Scholl SM, Fourquet A, Mosseri V, Durand 
JC, Pouillart P, Asselain B: Contralateral breast cancer: annual incidence 
and risk parameters.  J Clin Oncol 1995, 13:1578-1583.
4. Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of 
contralateral breast cancer.  Cancer Epidemiol Biomarkers Prev 1999, 
8:885-861.
5. Early Breast Cancer Trialists' Collaborative Group: Effects of 
chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: an overview of the randomized trials.  
Lancet 2005, 365:1687-1717.
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin 
WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu 
E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report 
of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J 
Natl Cancer Inst 1998, 90:1371-1388.
7. Powles T, Ashley S, Tidy A, Smith IE, Dowsett M: Twenty-year follow-up of 
the Royal Marsden randomized, double-blinded tamoxifen breast 
cancer preventive trial.  J Natl Cancer Inst 2007, 99:283-290.
8. Cuzik J, Forbes J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A: Long-
term results of tamoxifen prophylaxis for breast cancer - 96-months 
follow-up of the randomized IBIS-I trial.  J Natl Cancer Inst 2007, 
99:272-282.
Received: 15 July 2009 Accepted: 14 May 2010 
Published: 14 May 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/205 © 2010 Veronesi et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:205
Figure 3 Event-Free Survival (ER-positive patients).
log-rank test=0.13; p=0.72
TAM (n= 148)
FU (n= 159)
Time (months)
%
 
E
v
e
n
t
f
r
e
e
 
s
u
r
v
i
v
a
l
N° at risk     TAM     148    146    144    141    136     125   105     79      57       31      10       1        1         1 
           FU          159    154    149    145    141     132   116     86      62       33      14       0        0         0 Veronesi et al. BMC Cancer 2010, 10:205
http://www.biomedcentral.com/1471-2407/10/205
Page 8 of 8
9. Veronesi U, Maissonneuve P, Sacchini V, Rotmensz N, Boyle P: Tamoxifen 
for breast cancer among hysterectomised women.  Lancet 2002, 
359:1122-1124.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of 
cancer treatment.  Cancer 1981, 47:207-214.
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete 
observations.  J Am Stat Assoc 1958, 53:457-481.
12. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham L, Fisher B, Paik 
S, Wolmark N: Estrogen receptor status of primary breast cancer is 
predictive of estrogen receptor status of contralateral breast cancer.  J 
Natl Cancer Inst 2004, 96:516-523.
13. Delozier T, Switsers O, Genot JY, Ollivier JM, Héry M, Namer M, Fresney M, 
Kerbrat P, Veyret C, de Lafontan B, Janvier M, Macé-Lesech J: Delayed 
adjuvant tamoxifen: ten-year results of a collaborative randomized 
controlled trial in early breast cancer (TAM-02 trial).  Ann Oncol 2000, 
11:515-519.
14. Love RR, Olsen MR, Havighurst TC: Delayed adjuvant tamoxifen in 
postmenopausal women with axillary node-negative breast cancer: 
mortality over 10 years.  JNCI 1999, 91:1167-1168.
15. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of 
early breast cancer by hormonal, cytotoxic, or immune therapy.  Lancet 
1992, 339:3-17.
16. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early 
breast cancer: an overview of the randomised trials.  Lancet 1998, 
351:1451-1467.
17. Alkner S, Bendahl PO, Fernoe M, Nordenskjoeld B, Rydén L: Tamoxifen 
reduces the risk of contralateral breast cancer in premenopausal 
women: results from a controlled randomised trial.  Eur J Cancer 2009, 
45:2496-2502.
18. Merglen A, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Vinh-Hung V, 
Vlastos G, Chappuis PO, Castiglione M, Rapiti E, Bouchardy C: Hormonal 
therapy for oestrogen receptor-negative breast cancer is associated 
with higher disease-specific mortality.  Ann Oncol 2009, 20:857-861.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/205/prepub
doi: 10.1186/1471-2407-10-205
Cite this article as: Veronesi et al., Late tamoxifen in patients previously 
operated for breast cancer without postoperative tamoxifen: 5-year results of 
a single institution randomised study BMC Cancer 2010, 10:205